Extracorporeal shockwave therapy isn’t new. But the SoftWave platform uses a specific waveform with 230+ scientific publications across 20+ countries.
SoftWave generates controlled, unfocused shockwaves that penetrate deep into tissue. The waves stimulate local cellular signaling — increased blood flow, recruitment of stem cells already in your body, and reduced inflammatory response.
The treatment doesn’t repair tissue directly. It tells your body to do what it already knows how to do — but does poorly in chronic-injury cases where the signal got stuck.
Real regeneration, not symptom suppression.
Aggregated data from peer-reviewed studies on SoftWave TRT across tendon, ligament, joint, and soft-tissue conditions.
SoftWave research is strongest for chronic soft-tissue conditions that haven’t responded to conservative care.
One of the most-studied SoftWave indications. Strong evidence for patients who haven’t responded to stretching, orthotics, or PT.
Achilles, patellar, rotator-cuff, lateral epicondyle. Evidence base is well established for chronic tendon dysfunction.
Reduces pain and improves function in early-to-moderate OA. Doesn’t reverse damage but reduces inflammation and improves quality.
Persistent muscle and fascial irritation that hasn’t resolved through rest, stretching, or manual therapy alone.
Pick a time below — no referral, no insurance approval required for the initial evaluation.
Edit this HTML widget in Elementor and replace its content with your actual GHL calendar iframe embed code from Settings → Calendars → Embed Code.
If SoftWave is the right tool for your case, you’ll know after the evaluation.
